This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Chromium picolinate
- DrugBank Accession Number
- DB11255
- Background
Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor 1.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Chromium picolinate (DB11255)
- Weight
- Average: 418.3005
Monoisotopic: 418.013122035 - Chemical Formula
- C18H12CrN3O6
- Synonyms
- Chromium(III) picolinate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareBetibeglogene autotemcel The risk or severity of adverse effects can be increased when Chromium picolinate is combined with Betibeglogene autotemcel. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Administer vitamin supplements. Foods or supplements containing niacin (Vitamin B3) may improve the absorption of chromium.
- Take with foods containing vitamin C. Foods rich in vitamin C increase the absorption of chromium.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Chromium unknown 0R0008Q3JB 7440-47-3 VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromic cation ionic X1N4508KF1 16065-83-1 BFGKITSFLPAWGI-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image MENOPACE KAPSUL, 30 ADET Chromium picolinate (50 mcg) + Aminobenzoic acid (30 mg) + Ascorbic acid (45 mg) + Biotin (30 mcg) + Boron (2 mg) + Copper (1 mg) + Cyanocobalamin (9 mcg) + Folic acid (400 mcg) + Iodine (225 mcg) + Iron (12 mg) + Magnesium (100 mg) + Manganese (2 mg) + Niacin (20 mg) + Pantothenic acid (30 mg) + Pyridoxine (40 mg) + Riboflavin (5 mg) + Selenium (100 mcg) + Thiamine (10 mg) + Vitamin A (750 mcg) + Vitamin D (2.5 mcg) + Vitamin E (30 mg) + Zinc (15 mg) Capsule Oral NOBEL İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 2020-05-28 Turkey 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Divista Chromium picolinate (1000 ug/1) + Biotin (2 mg/1) + Cyanocobalamin (15 ug/1) + Folic acid (1 mg/1) + Omega-3-acid ethyl esters (300 mg/1) + Pyridoxine (25 mg/1) Capsule Oral Us Pharmaceutical Corporation 2010-07-10 2011-09-30 US 
Medi-10 Chromium picolinate (1 mg/1) + Acetylcysteine (200 mg/1) + Cholecalciferol (1000 [iU]/1) + Levomefolate calcium (2.5 mg/1) + Lipoic acid (200 mg/1) + Mecobalamin (2.5 mg/1) + Nicotinamide (10 mg/1) + Pyridoxal phosphate (20 mg/1) + Resveratrol (83 mg/1) + Ubidecarenone (16 mg/1) Capsule Oral Medicap Laboratories Inc. 2015-05-01 2016-01-12 US RE FAC-x Chromium picolinate (200 ug/1) + Ascorbic acid (200 mg/1) + Biotin (200 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (2.5 mg/1) + Cyanocobalamin (2500 ug/1) + Folic acid (2800 ug/1) + Lutein (500 ug/1) + Lycopene (500 ug/1) + Magnesium (100 mg/1) + Manganese sulfate (2.5 mg/1) + Nicotinamide (100 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (20 mg/1) + Selenomethionine (100 ug/1) + Thiamine mononitrate (20 mg/1) + Vitamin A (5000 [iU]/1) + Vitamin E (100 [iU]/1) + Zinc (15 mg/1) Tablet Oral River’s Edge Pharmaceuticals, LLC 2007-07-01 2011-01-13 US Vita-Rx Diabetic Vitamin Chromium picolinate (0.465 mg/1) + Ascorbic acid (120 mg/1) + Biotin (2.5 mg/1) + Cholecalciferol (0.0625 mg/1) + Folic acid (0.8 mg/1) + Lipoic acid (150 mg/1) + Mecobalamin (0.0025 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Riboflavin (1.7 mg/1) + Thiamine mononitrate (1.5 mg/1) + Ubidecarenone (50 mg/1) + alpha-Tocopherol acetate (10 mg/1) Capsule, gelatin coated Oral Pure Source, Llc 2015-08-11 Not applicable US Vita-Rx Diabetic Vitamin Chromium picolinate (0.465 mg/1) + Ascorbic acid (120 mg/1) + Biotin (2.5 mg/1) + Cholecalciferol (0.0625 mg/1) + Folic acid (0.8 mg/1) + Lipoic acid (150 mg/1) + Mecobalamin (0.0025 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Riboflavin (1.7 mg/1) + Thiamine mononitrate (1.5 mg/1) + Ubidecarenone (50 mg/1) + alpha-Tocopherol acetate (10 mg/1) Capsule, gelatin coated Oral Mas Management Group Inc. 2015-08-11 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pyridinecarboxylic acids and derivatives
- Direct Parent
- Pyridinecarboxylic acids
- Alternative Parents
- Heteroaromatic compounds / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic zwitterions / Organic oxides show 2 more
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Heteroaromatic compound / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic chromium salt / Organic nitrogen compound show 9 more
- Molecular Framework
- Not Available
- External Descriptors
- chromium coordination entity (CHEBI:50369)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S71T8B8Z6P
- CAS number
- 14639-25-9
- InChI Key
- CBDQOLKNTOMMTL-UHFFFAOYSA-K
- InChI
- InChI=1S/3C6H5NO2.Cr/c3*8-6(9)5-3-1-2-4-7-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3
- IUPAC Name
- chromium(3+) tris(pyridine-2-carboxylate)
- SMILES
- [Cr+3].[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1.[O-]C(=O)C1=NC=CC=C1
References
- General References
- Broadhurst CL, Domenico P: Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review. Diabetes Technol Ther. 2006 Dec;8(6):677-87. [Article]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Type 2 Diabetes Mellitus 1 1 Terminated Treatment Type 2 Diabetes Mellitus 1 Not Available Completed Prevention Atypical Depression / Obesity 1 Not Available Completed Treatment Impaired Glucose Tolerance / Metabolic Diseases / Obesity / Resistance, Insulin / Syndrome, Metabolic 1 Not Available Completed Treatment Type 2 Diabetes Mellitus 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral Capsule Oral Tablet Oral Tablet, film coated Oral Capsule, gelatin coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0312 mg/mL ALOGPS logP 2.9 ALOGPS logP -0.65 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 1 Chemaxon pKa (Strongest Basic) 5.52 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 53.02 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 41.62 m3·mol-1 Chemaxon Polarizability 10.94 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 03, 2015 16:51 / Updated at June 12, 2020 16:53